Analysts surveyed by Zacks estimate that Pfizer will report $15.5 billion in revenue for the quarter ended December 2025, representing a 10% year-over-year decline driven by waning COVID-19 vaccine sales. Consensus adjusted EPS is pegged at $0.92, reflecting margin pressure from increased R&D investment in oncology assets. Wall Street’s top-and-bottom-line forecasts range from $15.2 billion to $15.8 billion in revenue and $0.88 to $0.96 in EPS, with the narrow dispersion suggesting confidence in management’s guidance. Investors will also be watching forecasts for free cash flow, which Zacks projects at $4.3 billion, down from $5.8 billion a year earlier, and capital expenditures of approximately $1.1 billion as the company ramps up manufacturing capacity for its next-generation mRNA vaccines.

Pfizer faces looming loss of exclusivity for key blockbusters such as Xeljanz (JAK inhibitor) and Ibrance (CDK4/6 inhibitor) between 2026 and 2028, a shift expected to subtract $8–10 billion in peak annual revenues. However, management highlights a slate of late-stage candidates including the GLP-1/amylin dual agonists MET-097i and MET-233i, both granted Fast Track designation, and three new oncology approvals in breast, lung and prostate cancer over the next two years. The company’s vaccine pipeline also includes the RSV maternal immunization candidate, predicted to contribute $1.5 billion in peak sales. These programs underpin management’s forecast to generate $10–12 billion in incremental annual revenue by 2030, offsetting LOE pressure.

Despite a three-year stock price underperformance following its COVID-19 vaccine peak, Pfizer offers a 6.7% dividend yield, one of the highest in the large-cap pharma universe. Retail investor sentiment turned cautious late last year, with short interest rising 15% as of December, but institutional ownership remains steady at 68%. With a Dividend Coverage Ratio of 3.5x projected for 2026, the payout is deemed sustainable. Allka Research and other conservative analysts point to the yield as a compelling entry point for income-oriented portfolios, provided investors can tolerate near-term volatility tied to pipeline readouts.

The U.S. Centers for Medicare & Medicaid Services included three Pfizer products in its third negotiation cycle under the Medicare Drug Price Negotiation Program, marking the first time several Part B therapies are subject to price talks. This designation could pressure list prices by 15–20% starting in 2028 for products that represent approximately $3 billion in annual U.S. sales. Management has signaled readiness to absorb or partially offset these discounts through rebates and volume growth in private markets. Investors will monitor the details of final negotiated rates and the company’s strategy to defend margins in the Medicare segment.